Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, discusses how CRISPR technology has seen success and potential areas for future application.
In this interview, Kevin Davies, PhD, executive editor, The CRISPR Journal and GEN Biotechnology, and author of Editing Humanity: The CRISPR Revolution and the New Era of Genome Editing, discusses the various ways in which CRISPR technology has seen success and potential areas for future application.
Transcript
How have precision medicine and genomic editing changed since The Human Genome Project was launched?
In the aftermath of The Human Genome Project, there was some progress in gene editing using other technologies. But it's really CRISPR that has made gene editing a clinical reality. Hundreds of patients have either recently or are currently being treated using CRISPR.
CRISPR was developed around 2012 to 2013 in some landmark articles, most of them published in the journal Science, and from that time, scientists have built a toolbox that allows them to edit the DNA of all organisms—but of course, we're mostly interested in humans—and to tackle a growing list of diseases as well as use CRISPR in the context of CAR T [chimeric antigen receptor T-cell] therapies for various types of leukemia and other cancers. The progress is astonishing.
The Nobel Prize for the basic underlying technology was awarded to Jennifer Doudna [PhD] and Emmanuelle Charpantier [PhD], who had been collaborating on the early years of this technology; that was 2020. And now in 2023, we're seeing a growing number of clinical trials, and the most spectacular success so far has come in sickle cell disease. Dozens of patients have not only been successfully treated, we might say essentially cured of sickle cell disease, which when you think about the century-long history of sickle cell—from when it was first reported in the Western medical literature and the struggles that patients with sickle cell disease have experienced, and sometimes the outright discrimination—the fact that now some of these patients are seeing absolute cures, no pain crises, no blood transfusions, it is a stunning development. And we hope this can be translated to many other patients with many other diseases going forward.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More